topics / obesity
Tagged obesity.
- Animal only Adipotide (FTPP) A pro-apoptotic peptidomimetic that kills the blood vessels feeding white fat. It produced striking fat loss in obese mice and monkeys, but never cleared safety into meaningful human testing — the lone human trial enrolled four patients and reported no results.
- Preliminary human AOD-9604 A growth-hormone fragment marketed for fat loss. The human trials were small and short, the pivotal obesity study failed, and development was abandoned. Unapproved as a drug everywhere.
- Preliminary human Ecnoglutide A long-acting, cAMP-biased GLP-1 receptor agonist approved in China for type 2 diabetes and weight management, with genuine peer-reviewed Phase 3 data that is still confined to Chinese populations and not FDA-approved.
- Preliminary human Mazdutide: real Phase 3 data, but almost all of it from China A GLP-1/glucagon dual agonist approved in China for weight loss and diabetes, with genuine RCT evidence that is still sponsor-funded and single-country.
- Preliminary human Retatrutide An investigational triple-hormone agonist with striking weight-loss data in trials, but not yet FDA-approved and with no peer-reviewed Phase 3 results.
- Preliminary human Survodutide: Strong Phase 2 data and a first Phase 3 readout, but still investigational An investigational GLP-1/glucagon dual agonist with solid placebo-controlled Phase 2 trials and one positive Phase 3 topline, but no approval and no peer-reviewed Phase 3 data.